Topic
Collyrium
About: Collyrium is a research topic. Over the lifetime, 31 publications have been published within this topic receiving 244 citations.
Papers
TL;DR: The hypothesis that application of NGF on the eye can represent an alternative delivery route to promote the recovery of brain cells during degeneration, including neurons involved in learning and memory activities is strengthened.
Abstract: We have recently shown that conjunctivally applied nerve growth factor (NGF) in rats can reach the retina, the optic nerve and the CNS. In the present study, we investigated whether NGF application as collyrium can promote the recovery of chemically injured basal forebrain cholinergic neurons. NGF was administered on the eye of adult male mice previously treated i.c.v. with ibotenic acid to impair cholinergic pathways. Mice were tested in the passive avoidance test, and after 2 weeks of NGF administration were killed and the brains used for structural, biochemical and molecular analyses. The results showed that application of NGF on the eye surface protected choline acetyl transferase levels. These findings strengthen the hypothesis that application of NGF on the eye can represent an alternative delivery route to promote the recovery of brain cells during degeneration, including neurons involved in learning and memory activities.
59 citations
TL;DR: The hypothesis that β-AR blockade can efficiently counteract OIR is strengthened and it is suggested that topical eye application of propranolol can represent an alternative delivery route to systemic administration thus avoiding the risk of associated complications and side effects that could make this drug unsafe in the ROP treatment.
47 citations
Patent•
14 Nov 1989TL;DR: In this paper, the use of acetyl D-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of glaucoma has been described; the medicament may be administered orally or parenterally or be applied as a collyrium containing approximately 1-10% w/v of acyclic acid.
Abstract: The use is described of acetyl D-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of glaucoma. The medicament may be administered orally or parenterally or be applied as a collyrium containing approximately 1-10% w/v of acetyl D-carnitine.
42 citations
Patent•
6 May 2009
TL;DR: Collyrium for the treatment for patients suffering from conical cornea containing the riboflavin photosensitising substance and a surface-active agent to assist penetration of the collyrium in the corneal epithelium as discussed by the authors.
Abstract: Collyrium for the treatment for patients suffering from conical cornea containing the riboflavin photosensitising substance and a surface-active agent to assist penetration of the collyrium in the corneal epithelium; compared with normal collyria for the treatment of conical cornea, the product according to the invention has the advantage of not requiring the removal of the corneal epithelium, with the absence of pain for the patient, who does not need particular post treatment therapy, no longer complains of edema due to the removal of the epithelium and preserves the original corneal transparency.
23 citations
Patent•
27 Nov 1989TL;DR: The use of acetyl D-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of glaucoma was described in this paper. But the use of this drug was limited to a single application.
Abstract: The use is described of acetyl D-carnitine and its pharmacologically acceptable salts in the therapeutic treatment of glaucoma. The medicament may be administered orally or parenterally or be applied as a collyrium containing approximately 1-10 % w/v of acetyl D-carnitine.
18 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2020 | 1 |
| 2019 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2011 | 3 |